Targeting STEAP1 as an anticancer strategy

Hajime Nakamura; Yohei Arihara; Kohichi Takada

doi:10.3389/fonc.2023.1285661

Targeting STEAP1 as an anticancer strategy

Front Oncol. 2023 Oct 16:13:1285661. doi: 10.3389/fonc.2023.1285661. eCollection 2023.

Authors

Hajime Nakamura¹, Yohei Arihara¹, Kohichi Takada¹

Affiliation

¹ Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Abstract

Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.

Keywords: CAR-T therapy; STEAP1; antibody therapy; anticancer strategies; cancer vaccine.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported in part by the Japan Society for the Promotion of Science (grants C/19K08397, C/16K07178 to KT).